{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:29:23Z","timestamp":1790278163726,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Huntington\u2019s disease (HD) is caused by a cytosine adenine guanine-repeat expansion in the huntingtin gene. This results in the production of toxic mutant huntingtin protein (mHTT), which has an elongated polyglutamine (polyQ) stretch near the protein\u2019s N-terminal end. The pharmacological lowering of mHTT expression in the brain targets the underlying driver of HD and is one of the principal therapeutic strategies being pursued to slow or stop disease progression. This report describes the characterisation and validation of an assay designed to quantify mHTT in the cerebrospinal fluid of individuals with HD, for use in registrational clinical trials. The assay was optimised, and its performance was characterised with recombinant huntingtin protein (HTT) varying in overall and polyQ-repeat length. The assay was successfully validated by two independent laboratories in regulated bioanalytical environments and showed a steep signal increase as the polyQ stretch of recombinant HTTs pivoted from wild-type to mutant protein forms. Linear mixed effects modelling confirmed highly parallel concentration\u2013response curves for HTTs, with only a minor impact of individual slopes of the concentration\u2013response for different HTTs (typically\u2009&lt;\u20095% of the overall slope). This implies an equivalent quantitative signal behaviour for HTTs with differing polyQ-repeat lengths. The reported method may be a reliable biomarker tool with relevance across the spectrum of HD mutations, which can facilitate the clinical development of HTT-lowering therapies in HD.<\/jats:p>","DOI":"10.1038\/s41598-023-32630-4","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:50:55Z","timestamp":1680501055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies"],"prefix":"10.1038","volume":"13","author":[{"given":"Stephanie","family":"Vauleon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Massonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Manchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Buehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eginhard","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Boak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hawellek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"32630_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RA Roos","year":"2010","unstructured":"Roos, R. A. Huntington\u2019s disease: A clinical review. Orphanet J. Rare Dis. 5, 40. https:\/\/doi.org\/10.1186\/1750-1172-5-40 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"32630_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross, C. A. et al. Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204\u2013216. https:\/\/doi.org\/10.1038\/nrneurol.2014.24 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"32630_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi, S. J. et al. A biological classification of Huntington\u2019s disease: The Integrated Staging System. Lancet Neurol. 21, 632\u2013644. https:\/\/doi.org\/10.1016\/S1474-4422(22)00120-X (2022).","journal-title":"Lancet Neurol."},{"key":"32630_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/s1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi, S. J. et al. Potential disease-modifying therapies for Huntington\u2019s disease: Lessons learned and future opportunities. Lancet Neurol. 21, 645\u2013658. https:\/\/doi.org\/10.1016\/s1474-4422(22)00121-1 (2022).","journal-title":"Lancet Neurol."},{"key":"32630_CR5","doi-asserted-by":"publisher","first-page":"072302","DOI":"10.1103\/PhysRevLett.114.072302","volume":"114","author":"G Aad","year":"2015","unstructured":"Aad, G. et al. Measurements of the nuclear modification factor for jets in Pb\u2009+\u2009Pb collisions at radical(s)NN]\u2009=\u20092.76\u00a0TeV with the ATLAS detector. Phys. Rev. Lett. 114, 072302. https:\/\/doi.org\/10.1103\/PhysRevLett.114.072302 (2015).","journal-title":"Phys. Rev. Lett."},{"key":"32630_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.GIM.0000106165.74751.15","volume":"6","author":"NT Potter","year":"2004","unstructured":"Potter, N. T., Spector, E. B. & Prior, T. W. Technical standards and guidelines for Huntington disease testing. Genet. Med. 6, 61\u201365. https:\/\/doi.org\/10.1097\/01.GIM.0000106165.74751.15 (2004).","journal-title":"Genet. Med."},{"key":"32630_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1086\/301846","volume":"62","author":"The American College of Medical Genetics\/American Society of Human Genetics Huntington Disease Genetic Testing Working, G","year":"1998","unstructured":"The American College of Medical Genetics\/American Society of Human Genetics Huntington Disease Genetic Testing Working, G. Laboratory guidelines for Huntington disease genetic testing. Am. J. Hum. Genet. 62, 1243\u20131247 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"32630_CR8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou, F. & Humbert, S. The biology of Huntingtin. Neuron 89, 910\u2013926. https:\/\/doi.org\/10.1016\/j.neuron.2016.02.003 (2016).","journal-title":"Neuron"},{"key":"32630_CR9","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild, E. J. et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J. Clin. Invest. 125, 1979\u20131986. https:\/\/doi.org\/10.1172\/JCI80743 (2015).","journal-title":"J. Clin. Invest."},{"key":"32630_CR10","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci. Transl. Med. 10, eaat7108 (2018).","journal-title":"Sci. Transl. Med."},{"key":"32630_CR11","doi-asserted-by":"publisher","first-page":"12166","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell, A. L. et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci. Rep. 5, 12166. https:\/\/doi.org\/10.1038\/srep12166 (2015).","journal-title":"Sci. Rep."},{"key":"32630_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JHD-170269","volume":"6","author":"V Fodale","year":"2017","unstructured":"Fodale, V. et al. Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay. J. Huntingt. Dis. 6, 349\u2013361. https:\/\/doi.org\/10.3233\/JHD-170269 (2017).","journal-title":"J. Huntingt. Dis."},{"key":"32630_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J., Ghosh, R. & Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101, 801\u2013819. https:\/\/doi.org\/10.1016\/j.neuron.2019.01.039 (2019).","journal-title":"Neuron"},{"key":"32630_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0361-9230(01)00599-8","volume":"56","author":"J Ko","year":"2001","unstructured":"Ko, J., Ou, S. & Patterson, P. H. New anti-huntingtin monoclonal antibodies: Implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319\u2013329. https:\/\/doi.org\/10.1016\/s0361-9230(01)00599-8 (2001).","journal-title":"Brain Res. Bull."},{"key":"32630_CR15","doi-asserted-by":"publisher","first-page":"19152","DOI":"10.1038\/s41598-019-55202-x","volume":"9","author":"H Aviolat","year":"2019","unstructured":"Aviolat, H. et al. Assessing average somatic CAG repeat instability at the protein level. Sci. Rep. 9, 19152. https:\/\/doi.org\/10.1038\/s41598-019-55202-x (2019).","journal-title":"Sci. Rep."},{"key":"32630_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nsmb1234","volume":"14","author":"P Li","year":"2007","unstructured":"Li, P. et al. The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat. Struct. Mol. Biol. 14, 381\u2013387. https:\/\/doi.org\/10.1038\/nsmb1234 (2007).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"32630_CR17","unstructured":"U.S. Dept. of Health and Human Services, F., CDER, CVM. Guidance for Industry: Bioanalytical Method Validation. (2018)."},{"key":"32630_CR18","unstructured":"Piccoli, S. P., Sauer, J., Ackermann, B. et al. Points to consider document: Scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices. Biomarker Assay Collaborative Evidentiary Considerations Writing Group, Critical Path Institute. (2019)."},{"key":"32630_CR19","unstructured":"World Health Organization. UNDP\/World Bank\/WHO Special Programme for Research and Training in Tropical Diseases. Handbook: Good Laboratory Practice: Quality Practices for Regulated Non-clinical Research and Development. (2001)."},{"key":"32630_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64674","author":"R Kacher","year":"2021","unstructured":"Kacher, R. et al. Propensity for somatic expansion increases over the course of life in Huntington disease. Elife https:\/\/doi.org\/10.7554\/eLife.64674 (2021).","journal-title":"Elife"},{"key":"32630_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1523\/JNEUROSCI.1865-20.2020","volume":"41","author":"NS Caron","year":"2021","unstructured":"Caron, N. S. et al. Mutant Huntingtin is cleared from the brain via active mechanisms in Huntington disease. J. Neurosci. 41, 780\u2013796. https:\/\/doi.org\/10.1523\/JNEUROSCI.1865-20.2020 (2021).","journal-title":"J. Neurosci."},{"key":"32630_CR22","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting Huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316. https:\/\/doi.org\/10.1056\/NEJMoa1900907 (2019).","journal-title":"N. Engl. J. Med."},{"key":"32630_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1351\/pac198961091657","volume":"29","author":"GG Guilbault","year":"1991","unstructured":"Guilbault, G. G. & Hjelm, M. International union of pure and applied chemistry, commission on analytical nomenclature and clinical chemistry division. Nomenclature for automated and mechanised analysis, (recommendations 1989). Eur. J. Clin. Chem. Clin. Biochem. 29, 577\u2013585. https:\/\/doi.org\/10.1351\/pac198961091657 (1991).","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"32630_CR24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.4155\/bio-2017-0084","volume":"9","author":"J Tu","year":"2017","unstructured":"Tu, J. & Bennett, P. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: Pros and cons. Bioanalysis 9, 1107\u20131122. https:\/\/doi.org\/10.4155\/bio-2017-0084 (2017).","journal-title":"Bioanalysis"},{"key":"32630_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4155\/bio.13.292","volume":"6","author":"LF Stevenson","year":"2014","unstructured":"Stevenson, L. F. & Purushothama, S. Parallelism: Considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. Bioanalysis 6, 185\u2013198. https:\/\/doi.org\/10.4155\/bio.13.292 (2014).","journal-title":"Bioanalysis"},{"key":"32630_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0022-1759(92)90104-2","volume":"151","author":"S Amarasiri Fernando","year":"1992","unstructured":"Amarasiri Fernando, S. & Wilson, G. S. Studies of the \u2018hook\u2019 effect in the one-step sandwich immunoassay. J. Immunol. Methods 151, 47\u201366. https:\/\/doi.org\/10.1016\/0022-1759(92)90104-2 (1992).","journal-title":"J. Immunol. Methods"},{"key":"32630_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora, L. M. et al. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 Update. Ann. Intern. Med. 175, 1298\u20131304. https:\/\/doi.org\/10.7326\/M22-1460 (2022).","journal-title":"Ann. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32630-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:58:34Z","timestamp":1680501514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32630"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32630-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SV, KS, BM, MM, AB, ES, LB and DJH are full-time employees of F. Hoffmann-La Roche Ltd. NG is a full-time employee of ICON Bioanalytical Laboratories.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5332"}}